-
Something wrong with this record ?
Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment
JC. Higareda-Almaraz, JS. Ruiz-Moreno, J. Klimentova, D. Barbieri, R. Salvador-Gallego, R. Ly, IA. Valtierra-Gutierrez, C. Dinsart, GA. Rabinovich, J. Stulik, F. Rösl, B. Rincon-Orozco,
Language English Country Great Britain
Document type Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
NLK
BioMedCentral
from 2001-12-01
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Galectins metabolism MeSH
- Humans MeSH
- Tumor Microenvironment physiology MeSH
- Uterine Cervical Neoplasms metabolism pathology MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Galectin-7 (Gal-7) is negatively regulated in cervical cancer, and appears to be a link between the apoptotic response triggered by cancer and the anti-tumoral activity of the immune system. Our understanding of how cervical cancer cells and their molecular networks adapt in response to the expression of Gal-7 remains limited. METHODS: Meta-analysis of Gal-7 expression was conducted in three cervical cancer cohort studies and TCGA. In silico prediction and bisulfite sequencing were performed to inquire epigenetic alterations. To study the effect of Gal-7 on cervical cancer, we ectopically re-expressed it in the HeLa and SiHa cervical cancer cell lines, and analyzed their transcriptome and SILAC-based proteome. We also examined the tumor and microenvironment host cell transcriptomes after xenotransplantation into immunocompromised mice. Differences between samples were assessed with the Kruskall-Wallis, Dunn's Multiple Comparison and T tests. Kaplan-Meier and log-rank tests were used to determine overall survival. RESULTS: Gal-7 was constantly downregulated in our meta-analysis (p < 0.0001). Tumors with combined high Gal-7 and low galectin-1 expression (p = 0.0001) presented significantly better prognoses (p = 0.005). In silico and bisulfite sequencing assays showed de novo methylation in the Gal-7 promoter and first intron. Cells re-expressing Gal-7 showed a high apoptosis ratio (p < 0.05) and their xenografts displayed strong growth retardation (p < 0.001). Multiple gene modules and transcriptional regulators were modulated in response to Gal-7 reconstitution, both in cervical cancer cells and their microenvironments (FDR < 0.05 %). Most of these genes and modules were associated with tissue morphogenesis, metabolism, transport, chemokine activity, and immune response. These functional modules could exert the same effects in vitro and in vivo, even despite different compositions between HeLa and SiHa samples. CONCLUSIONS: Gal-7 re-expression affects the regulation of molecular networks in cervical cancer that are involved in diverse cancer hallmarks, such as metabolism, growth control, invasion and evasion of apoptosis. The effect of Gal-7 extends to the microenvironment, where networks involved in its configuration and in immune surveillance are particularly affected.
Department Biologie 2 Ludwig Maximilians Universität München Planegg Martinsried Germany
Division of Tumor Virology German Cancer Research Center 69 120 Heidelberg Germany
Division of Viral Transformation Mechanisms German Cancer Research Center 85764 Neuherberg Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017079
- 003
- CZ-PrNML
- 005
- 20180517093703.0
- 007
- ta
- 008
- 180515s2016 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12885-016-2700-8 $2 doi
- 035 __
- $a (PubMed)27558259
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Higareda-Almaraz, Juan Carlos $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. Institute for Diabetes and Cancer, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), 85764, Neuherberg, Germany.
- 245 10
- $a Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment / $c JC. Higareda-Almaraz, JS. Ruiz-Moreno, J. Klimentova, D. Barbieri, R. Salvador-Gallego, R. Ly, IA. Valtierra-Gutierrez, C. Dinsart, GA. Rabinovich, J. Stulik, F. Rösl, B. Rincon-Orozco,
- 520 9_
- $a BACKGROUND: Galectin-7 (Gal-7) is negatively regulated in cervical cancer, and appears to be a link between the apoptotic response triggered by cancer and the anti-tumoral activity of the immune system. Our understanding of how cervical cancer cells and their molecular networks adapt in response to the expression of Gal-7 remains limited. METHODS: Meta-analysis of Gal-7 expression was conducted in three cervical cancer cohort studies and TCGA. In silico prediction and bisulfite sequencing were performed to inquire epigenetic alterations. To study the effect of Gal-7 on cervical cancer, we ectopically re-expressed it in the HeLa and SiHa cervical cancer cell lines, and analyzed their transcriptome and SILAC-based proteome. We also examined the tumor and microenvironment host cell transcriptomes after xenotransplantation into immunocompromised mice. Differences between samples were assessed with the Kruskall-Wallis, Dunn's Multiple Comparison and T tests. Kaplan-Meier and log-rank tests were used to determine overall survival. RESULTS: Gal-7 was constantly downregulated in our meta-analysis (p < 0.0001). Tumors with combined high Gal-7 and low galectin-1 expression (p = 0.0001) presented significantly better prognoses (p = 0.005). In silico and bisulfite sequencing assays showed de novo methylation in the Gal-7 promoter and first intron. Cells re-expressing Gal-7 showed a high apoptosis ratio (p < 0.05) and their xenografts displayed strong growth retardation (p < 0.001). Multiple gene modules and transcriptional regulators were modulated in response to Gal-7 reconstitution, both in cervical cancer cells and their microenvironments (FDR < 0.05 %). Most of these genes and modules were associated with tissue morphogenesis, metabolism, transport, chemokine activity, and immune response. These functional modules could exert the same effects in vitro and in vivo, even despite different compositions between HeLa and SiHa samples. CONCLUSIONS: Gal-7 re-expression affects the regulation of molecular networks in cervical cancer that are involved in diverse cancer hallmarks, such as metabolism, growth control, invasion and evasion of apoptosis. The effect of Gal-7 extends to the microenvironment, where networks involved in its configuration and in immune surveillance are particularly affected.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a galektiny $x metabolismus $7 D037161
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádorové mikroprostředí $x fyziologie $7 D059016
- 650 _2
- $a nádory děložního čípku $x metabolismus $x patologie $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ruiz-Moreno, Juan S $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. Department of Internal Medicine/Infectious Diseases and Respiratory Medicine, Charité, 10117, Berlin, Germany.
- 700 1_
- $a Klimentova, Jana $u Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, 500 01, Hradec Králové, Czech Republic.
- 700 1_
- $a Barbieri, Daniela $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. Unit of Microbiology, Department of Diagnostic Medicine and Prevention, S. Orsola-Malpighi University Hospital, Bologna, Italy.
- 700 1_
- $a Salvador-Gallego, Raquel $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. Interfaculty Institute of Biochemistry, University of Tübingen, 72076, Tübingen, Germany.
- 700 1_
- $a Ly, Regina $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
- 700 1_
- $a Valtierra-Gutierrez, Ilse A $u Department Biologie II, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
- 700 1_
- $a Dinsart, Christiane $u Division of Tumor Virology, German Cancer Research Center (DKFZ), 69,120, Heidelberg, Germany.
- 700 1_
- $a Rabinovich, Gabriel A $u Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas, C1428, Ciudad de Buenos Aires, Argentina.
- 700 1_
- $a Stulik, Jiri $u Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, 500 01, Hradec Králové, Czech Republic.
- 700 1_
- $a Rösl, Frank $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. f.roesl@dkfz-heidelberg.de.
- 700 1_
- $a Rincon-Orozco, Bladimiro $u Division of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. blrincon@uis.edu.co. Microbiology School, Universidad Industrial de Santander, Carrera 27 con calle 9, 680,011, Bucaramanga, Colombia. blrincon@uis.edu.co.
- 773 0_
- $w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 16, č. - (2016), s. 680
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27558259 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180517093840 $b ABA008
- 999 __
- $a ok $b bmc $g 1300703 $s 1013919
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 16 $c - $d 680 $e 20160824 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
- LZP __
- $a Pubmed-20180515